Skip to main content
OpenTrials
Completed

NCT Number: NCT04489810

Digestion of Gluten in the Presence of Enzymes

This study evaluates the impact of two dietary supplements (Elevase® and DE111®) and of oatmeal properties on the digestion of gluten and starch and on the glycemic response.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Atlantia Food Clinical Trials

Cork, Ireland

About this study

RATIONALE Two important factors can influence the proportions of gluten and starch that resist digestion: (1) enzyme availability and specificity and (2) the structural properties of the food.

Elevase®, is a dietary supplement based on an enzyme preparation which effectively degrades gluten in vitro (Healey, Hall et al. unpublished). As it has also been found that the rate of wheat protein digestion can be increased in the presence of amylases (Smith, Pan et al. 2015), Elevase® is also enriched with amylase to aid in starch digestion.

The structural properties of food are influenced by numerous factors including meal preparation practices. Two common practices that can influence nutrient availability differently are heating vs. refrigerating (e.g. oat porridge vs. soaked and refrigerated oats).

Bacillus subtilis DE111® can produce and secrete many enzymes, including proteases, which, if secreted into the environment of the digestive tract, could support digestion and, in particular, the digestion of gluten. However, it is not clear whether diet supplementation with DE111 is a physiologically viable approach in terms of probiotic survival in the gastrointestinal tract.

PURPOSE The aims of this study are to better understand the impact of each of these factors and whether supplementation with probiotic spores is a viable option.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject has given written informed consent
  • Subject has an ileostomy stable for at least 3 months post-operative and shows normal stoma functions
  • Subject is otherwise healthy
  • Subject is available to participate in the study sessions on the proposed dates

Exclusion criteria

  • Subject has coeliac disease or allergy to wheat products and/or any other ingredients in the test meal and standard meals
  • Case of obstruction of the stoma in the past 3 months
  • Body mass index < 18 kg/m2 or > 30 kg/m2.
  • Diagnosed mouth, throat or active gastrointestinal pathology (other than ileostomy) that may affect normal ingestion and digestion of food.
  • History of pancreatic disease
  • Subject is immunocompromised (HIV positive, transplant patient, on antirejection medications, on a steroid for >30 days, or chemotherapy or radiotherapy within the last year)
  • Subject has Type 1 or Type 2 diabetes mellitus.
  • Subject has a history of bariatric surgery.
  • Subject has a history of drug and/or alcohol abuse at the time of enrolment
  • Subject is currently participating in another study, or plans to participate in another study during the study period
  • Women of child-bearing potential who do not use an acceptable method of contraception
  • Pregnant or nursing (lactating) women

Treatment and study plan

Placebo

Dietary Supplement

Maltodextrin capsule manufactured to mimic the Elevase® and DE111® capsules

Elevase®

Dietary Supplement

1 capsule containing 350 mg of Elevase®

DE111®

Dietary Supplement

1 capsule containing Bacillus subtilis DE111

Meal A

Other

Oatmeal porridge - serving of cooked oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL

Meal B

Other

Refrigerated oatmeal - serving of refrigerated oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL

Primary outcomes

  1. Undigested wheat protein

    Time frame: 9-hour period after the test meal

    Difference between the mean concentration of undigested wheat protein in ileal effluent samples.

Secondary outcomes

  1. Vegetative DE111 cells

    Time frame: 9-hour period after the test meal

    Mean concentration of DE111® cells recovered in the ileal effluent in the vegetative state.

  2. Glycemic response

    Time frame: At baseline, and at different time-points during 9 hours after after consuming the test meal.

    Difference between the mean area under the glucose concentration (measured in the interstitial fluid) curves following each treatment

  3. Undigested starch

    Time frame: At baseline and once every hour in the 9-hour period after consumption of the test meal.

    Difference between the mean concentration of undigested starch in ileal effluent samples.

  4. Undigested food particles

    Time frame: 9-hour period after the test meal

    Pictures of undigested foods particles and microscopy will be combined for a combined assessment of macro- and micro- structural characteristics of the food particles recovered in ileal effluent samples.

Sponsors and collaborators

Lead sponsor

The Archer-Daniels-Midland Company

Industry

Collaborators

  • Atlantia Food Clinical Trials
  • Teagasc

Registry information

Official study title

GlutDigest - Enzymes-assisted Gluten Digestion

Acronym: GlutDigest

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Jul 28, 2020
Registry last updated
Apr 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.